A. Aspartate transaminase/alkaline phosphatase levels of at least 5 times normal and hypertension in excess of 150/100 mmHg B. Total bilirubin > 5 mg/dL, serum creatinine > 1.2 mg/dL, and weight gain > 5% C. Bilirubin ≥ 2 mg/dL plus 2 or more of the following: hepatomegaly, ascites, and weight gain > 5% D. Bilirubin > 5 mg/dL, albumin < 2.5 mg/dL, and INR > 2 E. Unsure

A. Antagonism of prostaglandins in the local vasculature in the liver B. Inhibition of vitamin K-dependent procoagulant proteins C. Antithrombin III inhibition coupled with inhibition of Factor Xa D. Anti-inflammatory and antioxidant effects through interaction with the endothelial cell membrane, coupled with an antithrombotic and an antiplatelet aggregation effect E. Unsure

A. Use for established VOD/SOS following allogeneic hematopoietic stem cell transplant (HSCT) in adult and pediatric patients B. Use as prophylaxis for VOD/SOS for adult and pediatric patients undergoing allogeneic HSCT C. Use as prophylaxis for VOD/SOS for adult patients undergoing either autologous or allogeneic HSCT with a busulfan-containing conditioning regimen D. Use in combination with either low-dose heparin or methylprednisolone as a second-line treatment for established VOD/SOS E. Unsure